Purinethol
(Mercaptopurine)ApprovedSmall molecule
Mercaptopurine is used to treat certain types of cancer, particularly acute leukemia, and autoimmune diseases like inflammatory bowel disease by suppressing the immune system and stopping cancer cells from growing.[2] Purinethol is currently approved and in use across 23 indications[4].[1]
Purinethol is one of 411 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Approved.
23
Indications
144
Total Trials
37
Active Trials
410
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Purinethol
SStason
Approved
Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia82 trials
Show 79 more trials
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00400946·800 enrolled
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT05157971·24 enrolled
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting·—·Phase 2·NCT06918431·53 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Active, not recruiting·—·Phase 3·NCT03020030·560 enrolled
Acute Promyelocytic Leukemia8 trials
Show 5 more trials
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled
Leukemia6 trials
Lymphoblastic Lymphoma5 trials
B Acute Lymphoblastic Leukemia5 trials
Show 2 more trials
25 more indications
Lymphoma4 trials
T-cell acute lymphoblastic leukemia4 trials
B-cell acute lymphoblastic leukemia3 trials
Adult Acute Lymphoblastic Leukemia3 trials
Treatment2 trials
Langerhans Cell Histiocytosis2 trials
Acute Leukemia of Ambiguous Lineage2 trials
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled
Myelodysplastic Syndrome1 trial
Brain Neoplasm1 trial
Precursor B-Cell Acute Lymphoblastic Leukemia1 trial
Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial
Bone Marrow Transplantation1 trial
Hematologic Malignancies1 trial
AIN1 trial
Fasting Conditions1 trial
Ulcerative Colitis1 trial
Mercaptopurine Therapy in Ulcerative Colitis
Unknown status·—·Phase 3·NCT02910245·136 enrolled
Inflammatory Disease1 trial
Bone1 trial
ALL Backbone in AYAs
Not yet recruiting·—·Phase 2·NCT07227584·67 enrolled
Randomized Controlled Trial1 trial
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Completed·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT02177071·211 enrolled
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
PURINETHOL
NDA NDA009053
Apr 28, 2014
PURIXAN
NDA NDA205919
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Purinethol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Mercaptopurine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]